Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3512MR)

This product GTTS-WQ3512MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3512MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6772MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ10539MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ3351MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ1815MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ12578MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ1442MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ9820MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ12087MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW